May 2026 Apimeds Pharmaceuticals US and Lōkahi Therapeutics announced that the U.S. FDA scheduled a Type C meeting for LT-100 (Apitox), a bee venom-derived biologic, supporting its regulatory development for the treatment of knee osteoarthritis.
January 2026 Stallergenes Greer entered into an agreement to acquire Entomon S.r.l., an Italian producer of pharmaceutical-grade stinging insect venom extracts, strengthening its manufacturing capabilities and raw material supply for venom immunotherapy products.